Cantor Fitzgerald Maintains Overweight on Sanara MedTech, Lowers Price Target to $44
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Ross Osborn has maintained an Overweight rating on Sanara MedTech (NASDAQ:SMTI) but lowered the price target from $49 to $44.

March 27, 2024 | 1:57 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald maintains an Overweight rating on Sanara MedTech but reduces the price target from $49 to $44.
While the maintenance of an Overweight rating suggests continued confidence in Sanara MedTech's fundamentals and growth prospects, the reduction in the price target could reflect adjustments in valuation metrics or market conditions. This mixed signal might lead to short-term uncertainty among investors, potentially stabilizing the stock price as the market digests the implications.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100